Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of brigatinib (AP26113) in lymphoma and non-small cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Non-small-cell Lung
• Lymphoma Large-cell Anaplastic

Drugs mentioned

• Brigatinib (brigatinib)

Snippet

Sponsor: Ariad Pharmaceuticals | Conditions: Lymphoma, Large-Cell, Anaplastic, Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-06-21